SoloRiff

Cold outreach to Biotech companies

The buyer is a Biotech Project Manager, who is primarily measured on the timely delivery of projects within budget. They respond to outreach that demonstrates an understanding of their unique regulatory hurdles and timelines, particularly around clinical trials and product development phases. Highlighting solutions that streamline compliance processes or enhance project efficiency will capture their attention.

Written and maintained by the SoloRiff team, who build outbound software and run outbound with it. The figures below are our own: we measured 573 biotech company domains over public DNS on 2026-09-03. Last updated 2026-09-03.

What actually hurts

  • regulatory approval delays
  • budget overruns
  • project timeline pressures
  • data management issues

The playbook

  1. 01

    Identify clinical trial milestones

    Research recent announcements about clinical trials in biotech companies. Use databases like ClinicalTrials.gov to find companies that have just initiated trials. These companies are often seeking solutions to streamline their processes during this critical phase.

  2. 02

    Pinpoint budget constraints

    Look for biotech firms that have recently secured funding through rounds or grants. Use Crunchbase or similar platforms to filter for companies that raised funds within the last 6 months, as they are likely to be evaluating new partnerships to maximize their investments.

  3. 03

    Craft a message around regulatory challenges

    Compose your outreach by addressing specific regulatory challenges faced by biotech firms, such as FDA submission processes. Reference recent changes in regulations that may impact their projects, showcasing your knowledge of their industry environment.

  4. 04

    Anticipate objections about timing

    Prepare to address concerns about timing in your follow-up. Many project managers are hesitant to engage if they believe their schedules are too tight. Offer a flexible meeting time, suggesting a brief 15-minute chat to discuss how you can alleviate their current pressures.

  5. 05

    Follow up after key conferences

    After major biotech conferences, reach out to attendees who showed interest in topics related to your offering. Use attendee lists from events like BIO International Convention to connect with prospects who just engaged in discussions about improving project efficiency.

Can biotech companies even receive your mail?

We measured the DNS of 573 biotech companies, sampled evenly across company sizes, to see how many authenticate their own email. It matters in both directions: a domain that does not authenticate is a domain whose team is used to mail going missing — and if your own domain is in the gap, yours is the mail going missing.

1–10 employees
27%
11–50
37.7%
51–200
47%
201–1,000
60.3%
1,000+
84.3%

Publishes a DMARC policy of quarantine or reject — the domain actually asks receivers to act on failures.

The gap is the finding: 27% of 1–10-person companies against 84.3% of the largest — 57 points apart. Small companies are where the unauthenticated domains are, and small companies are who most cold outreach is aimed at.

Where does your domain sit?

Same three lookups, run live against your domain. Nothing is stored and nothing is emailed to you.

How this was measured

Company domains were sampled within employee-count bands, then queried over public DNS for SPF (TXT at the apex), DMARC (TXT at _dmarc.) and MX. One domain per company, deduplicated. Anyone can reproduce any single row of this with dig.

DKIM is deliberately absent. A DKIM key lives under a selector that cannot be enumerated from outside the domain, so a company with flawless DKIM under a name we did not guess would be counted as having none. That would measure our guess list, not the industry.

Domains with no MX record are excluded rather than counted as failures — parked and redirect-only domains would otherwise drag every figure down and make the result an artefact of the sample.

Sampled within bands, so this describes the population of companies, not of employees: a 10-person company counts once, as does a 10,000-person one. Each band is at least 60 domains; bands below that are not published. Figures are percentages of the sample, not of the whole industry, and we publish no company names — only counts.

Measured 2026-09-03. Re-measured monthly.

The full census across every industry — sortable, with sample sizes, free to reuse under CC BY 4.0.

Subject lines that fit

  • Streamlining your clinical trials
  • Tackling regulatory hurdles together
  • Enhancing project efficiency

Questions

Why do biotech project managers ignore cold emails?
Biotech project managers often receive numerous outreach attempts and may ignore cold emails due to lack of personalization or relevance. If the email doesn’t directly address their specific regulatory challenges or project timelines, it risks being overlooked in favor of more tailored communications.
What triggers a response from biotech project managers?
A strong understanding of the regulatory landscape and how it impacts their projects can trigger a response. Additionally, providing insights on improving efficiency or compliance in clinical trials is likely to catch their attention, especially if it aligns with their current pain points.
What common mistakes do sellers make when contacting biotech firms?
Many sellers fail to demonstrate industry knowledge or address specific challenges faced by biotech companies. Generic outreach that does not consider the unique regulatory and project management complexities of biotech projects often results in low engagement from project managers.
How can sellers effectively engage biotech project managers?
Sellers can effectively engage biotech project managers by referencing recent industry developments or regulatory changes that impact their projects. Tailoring messages to highlight solutions that specifically address their needs and pain points will improve the chances of a positive response.

Or have it run itself

SoloRiff does every step above on its own — finds the companies, finds the people, writes each of them individually, and handles the replies. Drop your URL and watch it work before you sign up for anything.

Try it on your site